biote Corp.
About biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $192.2M
- Net income
- $27.0M
- Total assets
- $107.6M
- Market cap
- $71.0M
- Operating margin
- 18.5%
- Net margin
- 16.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $192.2M
- Operating expenses
- $156.7M
- Operating income
- $35.6M
- Income tax
- $6.0M
- Net income
- $31.6M
- EPS (basic)
- $0.86
- EPS (diluted)
- $0.74
Balance sheet
- Total assets
- $107.6M
- Current assets
- $54.7M
- Total liabilities
- $158.0M
- Current liabilities
- $45.0M
- Shareholders’ equity
- -$50.4M
Cash flow
- Operating cash flow
- $35.2M
- Investing cash flow
- -$6.9M
- Financing cash flow
- -$43.6M
- Net cash flow
- -$15.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $71.0M
- P/E ratio
- 3.2
- EPS (diluted)
- $0.74
- Shares outstanding
- 30.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 27, 2022
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $27.0M in FY2025.
- Revenue grew 17% from FY2022 to FY2025.
- Trading 49% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 3.2.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review biote Corp..
Write a review
News about biote Corp.
News & sentiment via Polygon.io
